title: Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice.
abstract: Type III secreted proteins from Escherichia coli O157:H7 are involved in the attachment of the organism to mammalian cells and have been shown to be effective vaccine components capable of reducing colonization of cattle by the organism. In the current study, we used a streptomycin-treated mouse model to evaluate the efficacy of subcutaneous vs intranasal administration of the vaccine. Following immunization, mice were infected with E. coli O157:H7 and feces were monitored for shedding. Immune responses against EspA and Tir were also monitored. Subcutaneous immunization of mice with type III secreted proteins induced significant EspA- and Tir-specific serum IgG antibodies but did not significantly induce any antigen-specific IgA in feces, whereas intranasal immunization elicited significant EspA- and Tir-specific serum IgG antibodies with some animals developing antigen-specific IgA in feces. Only mice that were immunized intranasally with formulations containing mucosal adjuvants, either cholera toxin or CpG-containing oligonucleotides, showed decreased E. coli O157:H7 shedding following experimental infection. Mice immunized subcutaneously with type III secreted proteins did not shed E. coli in feces. These results demonstrate the potential for the use of type III secreted proteins in mucosal vaccine formulations to prevent colonization and shedding of E. coli O157:H7.
authors.affiliation: Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada S7N 5E3. babiuks@inspection.gc.ca
authors.forename: Shawn
authors.initials: S
authors.lastname: Babiuk
authors.forename: David J
authors.initials: DJ
authors.lastname: Asper
authors.forename: Dragan
authors.initials: D
authors.lastname: Rogan
authors.forename: George K
authors.initials: GK
authors.lastname: Mutwiri
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Potter
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D004927:Escherichia coli Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D019453:Escherichia coli O157 / Q000276:immunology / Q000502:physiology*; D029968:Escherichia coli Proteins / Q000008:administration & dosage* / Q000276:immunology; D022361:Escherichia coli Vaccines / Q000008:administration & dosage* / Q000276:immunology; D005243:Feces / Q000382:microbiology*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G